Information Provided By:
Fly News Breaks for January 11, 2016
VRTX
Jan 11, 2016 | 06:39 EDT
Piper Jaffray analyst Edward Tenthoff recommends looking past the soft Q4 revenue and 2016 outlooks from Vertex Pharmaceuticals. He views the 2016 guidance as conservative and still wants to own the stock for the Orkambi launch. Tenthoff reiterates an Overweight rating on Vertex with a $180 price target.
News For VRTX From the Last 2 Days
There are no results for your query VRTX